Glenmede Trust Co. NA Acquires 109,283 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Glenmede Trust Co. NA raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 487,131 shares of the biopharmaceutical company's stock after acquiring an additional 109,283 shares during the quarter. Glenmede Trust Co. NA owned approximately 0.38% of Halozyme Therapeutics worth $27,883,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Boston Trust Walden Corp purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $23,211,000. Swedbank AB purchased a new stake in shares of Halozyme Therapeutics in the first quarter worth $13,927,000. Segall Bryant & Hamill LLC raised its position in shares of Halozyme Therapeutics by 16.3% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company's stock valued at $20,330,000 after purchasing an additional 49,856 shares during the period. Creative Planning lifted its stake in shares of Halozyme Therapeutics by 43.2% during the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company's stock valued at $1,953,000 after buying an additional 11,249 shares in the last quarter. Finally, Boston Partners boosted its holdings in Halozyme Therapeutics by 14.1% in the 1st quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company's stock worth $25,500,000 after buying an additional 77,976 shares during the period. Institutional investors own 97.79% of the company's stock.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total value of $590,900.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares of the company's stock, valued at $39,988,802.96. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 60,000 shares of company stock valued at $3,425,000 in the last three months. Corporate insiders own 2.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on HALO. JMP Securities raised their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a report on Friday, November 1st. Wells Fargo & Company downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Piper Sandler upped their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a research note on Monday, November 4th. TD Cowen increased their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. Finally, Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $61.11.

Halozyme Therapeutics Price Performance

HALO traded up $0.68 during trading hours on Thursday, hitting $48.47. The company's stock had a trading volume of 963,013 shares, compared to its average volume of 1,375,309. The stock has a market cap of $6.17 billion, a price-to-earnings ratio of 16.05, a P/E/G ratio of 0.43 and a beta of 1.29. The business's 50-day moving average price is $53.72 and its 200-day moving average price is $53.67. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.